Sens. Clinton, Murray Question FDA Timing On Plan B In Letter To Leavitt
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter to HHS Secretary notes FDA announced concerns about dual status marketing of Plan B more than one year after receiving the proposal from Barr.
You may also be interested in...
FDA Approps Bill Debate Could Include “Controversial Amendments,” Sen. Hatch Says
Amendments on drug importation, Plan B and follow-on biologics could be brought to the Senate floor during debate on the Agriculture appropriations measure.
FDA Approps Bill Debate Could Include “Controversial Amendments,” Sen. Hatch Says
Amendments on drug importation, Plan B and follow-on biologics could be brought to the Senate floor during debate on the Agriculture appropriations measure.
FDA Women’s Health Director Resigns Over Plan B
Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”